Hims & Hers Health, Inc. (NYSE:HIMS – Get Rating) has been given an average rating of "Hold" by the eight analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $7.38.

A number of research analysts have recently issued reports on the stock. SVB Leerink boosted their price target on shares of Hims & Hers Health from $4.00 to $5.00 and gave the stock an "underperform" rating in a research report on Tuesday, August 9th. Credit Suisse Group boosted their price target on shares of Hims & Hers Health from $7.00 to $8.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 10th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Hims & Hers Health from $7.00 to $8.00 in a research report on Wednesday, August 10th. Guggenheim lifted their price objective on shares of Hims & Hers Health to $12.00 in a research note on Monday, August 15th. Finally, Truist Financial began coverage on shares of Hims & Hers Health in a research note on Wednesday, September 7th. They issued a "hold" rating and a $7.00 price objective for the company.

Insiders Place Their Bets

In related news, insider Irene Becklund sold 11,002 shares of the business's stock in a transaction dated Friday, September 9th. The shares were sold at an average price of $6.64, for a total value of $73,053.28. Following the transaction, the insider now directly owns 2,715 shares of the company's stock, valued at approximately $18,027.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Lynne Chou O'keefe sold 10,046 shares of the business's stock in a transaction dated Tuesday, September 20th. The shares were sold at an average price of $5.68, for a total value of $57,061.28. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Irene Becklund sold 11,002 shares of the business's stock in a transaction dated Friday, September 9th. The stock was sold at an average price of $6.64, for a total transaction of $73,053.28. Following the completion of the transaction, the insider now directly owns 2,715 shares in the company, valued at $18,027.60. The disclosure for this sale can be found here. Insiders have sold 51,047 shares of company stock valued at $287,364 in the last three months. 35.22% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $5.38 on Wednesday. The business has a 50 day moving average of $6.20 and a 200-day moving average of $5.12. Hims & Hers Health has a 1 year low of $2.72 and a 1 year high of $9.19. The company has a market capitalization of $1.10 billion, a P/E ratio of -13.12 and a beta of 0.46.

Hims & Hers Health (NYSE:HIMS – Get Rating) last posted its earnings results on Monday, August 8th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). Hims & Hers Health had a negative net margin of 22.22% and a negative return on equity of 23.24%. The business had revenue of $113.60 million for the quarter, compared to the consensus estimate of $103.89 million. During the same period last year, the company earned ($0.08) EPS. The firm's revenue was up 89.0% compared to the same quarter last year. Equities analysts anticipate that Hims & Hers Health will post -0.36 EPS for the current year.

About Hims & Hers Health

(Get Rating)

Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.

Read More

• Get a free copy of the StockNews.com research report on Hims & Hers Health (HIMS)
• Defensive Stocks For A Volatile Market
• Will UPS Be Next to Deliver a Warning?
• SunPower Is Ready To Power Up Triple-Digit Earnings Gains
• Is This the Darkest Before the Dawn for Gap Stock?
• Build A Better Tech Portfolio With Jabil Inc.

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.